Jacob Jeppesen

Chief Scientific Officer Alveus Therapeutics

Copenhagen, Capital Region of Denmark, Denmark

About

Skilled leader, scientist and pre-clinical project manager in drug discovery with strong academic background within metabolism, physiology, type 2 diabetes and obesity. Internationally experienced and strong track record of driving projects within academia, and in the pharmaceutical industry in a global organization. Expertise in human and molecular physiology. Patient centric focus in drug discovery and development providing clinical knowledge, and excellent translation of pre-clinical science into a clinical setting. Open-minded, positive and committed person valuing responsibility and influence in work. Recognized for result orientation, communication capabilities and attitude to work. Thrives on hard work with parallel tasks and comfortable in both team based projects and independent tasks. Specialties: Driving change and innovation, leadership, strong analytical skill and innovative mindset, project management, patient focussed, metabolic diseases, type 2 diabetes, obesity.

Experience

  • Chief Scientific Officer at Alveus Therapeutics
    Mar 2024 - Present · 2 yrs 4 mos

  • Novo Nordisk (9 yrs 11 mos)
    • Vice President - Type 2 Diabetes and Cardiovascular Disease Research
      Feb 2022 - Mar 2024 · 2 yrs 2 mos

    • Director, Head of Diabetes & Metabolism Biology
      Aug 2020 - Feb 2022 · 1 yr 7 mos

    • Scientific Director
      Aug 2018 - Aug 2020 · 2 yrs 1 mo

  • Visiting Scientist at Massachusetts Institute of Technology
    Sep 2018 - Aug 2020 · 2 yrs

    Department of Biological Engineering

  • Visiting Scientist at Whitehead Institute for Biomedical Research
    Aug 2018 - Aug 2020 · 2 yrs 1 mo

    Laboratory of Richard Young

  • Associate Professor at Faculty of Science, University of Copenhagen
    Nov 2013 - May 2014 · 7 mos

    Research focus: Regulation of lipid metabolism in health and disease Pre-clinical research - Lipid binding proteins in lipid transport and oxidation - Molecular targets for regulation of lipid oxidative capacity - Targeting lipid oxidation - implications for insulin resistance Clinical research - FA type dependent regulation of FA oxidative capacity - implications for development of insulin resistance